Anika Therapeutics Inc

Anika Therapeutics raised its full-year 2026 revenue and adjusted EBITDA guidance following a second quarter in which total revenue grew 16% to $32.6 million and gross margin expanded to 65%. Commercial channel revenue reached a record $13.9 million, up 17% year over year, while international revenue also hit a record $12.6 million, a 22% increase driven by market share gains in osteoarthritis pain management and higher contributions from regenerative solutions. OEM channel revenue rose 14% to $18.7 million, supported by favorable order timing and Monovisc unit volumes exceeding projections. Adjusted EBITDA was $7.1 million, the highest since 2020, and net income was $3.3 million. The company now expects total revenue growth of 5% to 10%, up from a prior range of 1% to 9%, and adjusted EBITDA margin of 13% to 17%, up from 5% to 10%. For 2027, Anika introduced a new policy to exclude revenue from unapproved products such as Hyalofast, resulting in a forecast of 0% to 5% total company revenue growth.

Several biotech stocks reached 52-week highs on July 29, 2026, driven by second-quarter financial results and clinical updates. Anika Therapeutics rose over 6% to $17.75 after reporting second-quarter revenue of $32.6 million, a 17% year-over-year increase, and net income of $3.3 million, while revising its 2026 total revenue growth guidance to 5% to 10%. Chemed Corporation climbed over 4% to $551.68 as its second-quarter revenue grew 8.8% to $673 million, with its VITAS Healthcare unit contributing $443.4 million in patient revenue and a 9% increase in admissions, and the company raised its full-year revenue growth estimate to 8.25% to 9.25%. ICU Medical hit an intraday high of $170.48 ahead of its August 6 earnings report, following a first quarter in which infusion systems product revenue grew 9% to $179 million despite a 12% overall GAAP revenue decline to $530 million due to a divestiture. Neurocrine Biosciences reached $183.50 ahead of its July 30 earnings release, after first-quarter net product sales surged 44% to $811 million and the company acquired Soleno Therapeutics in May 2026. Royalty Pharma touched $60.44, reporting a 13% increase in first-quarter royalty receipts to $887 million and projecting full-year royalty receipts between $3.32 billion and $3.45 billion, with second-quarter results due on August 5.

Anika Therapeutics raised its full-year 2026 guidance, now projecting total company revenue growth of 5% to 10% and an adjusted EBITDA margin of 13% to 17%, up from a prior margin expectation of 5% to 10%. The company reported second-quarter total revenue of $32.6 million, a 16% year-over-year increase, with commercial channel revenue growing 17% to $13.9 million and international revenue reaching a record $12.6 million, up 22%. Gross margin expanded to 65% from 51% a year earlier, and adjusted EBITDA hit $7.1 million, representing a 22% margin. Management said the mid-60s gross margin level is sustainable, driven by operational improvements, while noting that OEM pricing remains a headwind offset by volume. For 2027, Anika adopted a new revenue guidance practice that excludes unapproved products, removing a previously implied $3 million of U.S. Hyalofast sales, and still expects total company revenue growth of 0% to 5%.